Melanoma — Research Intelligence Dashboard
Prototype dashboard for architecture validation. Metrics shown are illustrative until registry enrichment and GRMI calculation engine are live.
Executive Summary
Data snapshot: February 2026
491
Total Active Trials
ClinicalTrials.gov Registry Subset
143
New Trials
Rolling 12 Months
17.7%
Phase I Density
Percentage
22
Distinct Biomarkers
Active
Accelerating
Research Momentum Classification (Rolling 12-Month Model)
Global Research Momentum Index (GRMI)
89
GRMI ScoreComposite index weighted as:
• Trial Velocity (30%)
• Early-Phase Density (25%)
• Biomarker Diversity (20%)
• Modality Expansion (15%)
• Geographic Spread (10%)
• Trial Velocity (30%)
• Early-Phase Density (25%)
• Biomarker Diversity (20%)
• Modality Expansion (15%)
• Geographic Spread (10%)
Accelerating
12-Month Trend
Component Breakdown
87
Trial Velocity Score
76
Early Phase Density
82
Biomarker Diversity
94
Modality Expansion
96
Geographic Spread
Phase & Modality Distribution
Phase Distribution
Modality Distribution
Geographic Spread
58
Countries Active
234
United States
Active Trials
178
Europe
Active Trials
79
Asia-Pacific
Active Trials
12-Month Geographic Expansion:+5 new countries, +38 new trial sites
Centers Actively Studying This Area
Institutions listed based on active melanoma trial count ≥ 30 (ClinicalTrials.gov registry analysis).
| Institution Name | Active Trials | Phase I % | Dominant Modality | Distinct Biomarkers |
|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 54 | 24% | Checkpoint Inhibitor | 17 |
| MD Anderson Cancer Center | 61 | 27% | Combination | 19 |
| Dana-Farber Cancer Institute | 44 | 21% | Targeted Therapy | 15 |
| Mayo Clinic | 38 | 19% | Checkpoint Inhibitor | 13 |
| University of California, Los Angeles | 41 | 29% | Combination | 16 |
| Johns Hopkins Hospital | 36 | 23% | Targeted Therapy | 14 |
Institutional Research Footprint Overlay
Institutional Overlay (Phase II Modeling)
This section will display global baseline vs. selected institution metrics side-by-side, enabling comparative analysis of institutional research positioning.
What This Signals
Checkpoint inhibitor dominance established
221 checkpoint inhibitor trials active, reflecting PD-1/CTLA-4 translational maturity
BRAF mutation stratification mature
BRAF V600E/K-targeted therapy ecosystem well-established with combination strategies
Geographic dispersion highest among flagship models
58 countries active, reflecting global immunotherapy research distribution
Translational maturity evident
Phase I density at 17.7%, reflecting a stable-mature ecosystem with established treatment paradigms (checkpoint inhibitors, BRAF/MEK targeting)